Fate Therapeutics (FATE) Total Current Liabilities (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Total Current Liabilities came in at $30.7 million in Q1 2026, up 8.98% YoY from $28.2 million in Q1 2025, and down 14.92% on a QoQ basis from $36.1 million in Q4 2025.
Fate Therapeutics (FATE) Total Current Liabilities (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Total Current Liabilities data on file, last reported at $30.7 million in Q1 2026.
- Quarterly Total Current Liabilities rose 8.98% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 million (up 8.98% YoY) and the FY2025 annual result came in at $36.1 million, down 6.36% from the prior year.
- Total Current Liabilities fell to $30.7 million in Q1 2026, from $36.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $114.1 million in Q4 2022 to a low of $28.1 million in Q3 2025.
- A 5-year average of $51.1 million and a median of $39.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 40.31% — and 2023, when it tumbled 65.72%.
- Tracing FATE's Total Current Liabilities over 5 years: stood at $114.1 million in 2022, then plunged by 65.72% to $39.1 million in 2023, then declined by 1.46% to $38.5 million in 2024, then slipped by 6.36% to $36.1 million in 2025, then retreated by 14.92% to $30.7 million in 2026.
- The last three Total Current Liabilities figures came in at $30.7 million (Q1 2026), $36.1 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 30.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.69 Mn |
| Dec 31, 2025 | 36.07 Mn |
| Sep 30, 2025 | 28.11 Mn |
| Jun 30, 2025 | 28.67 Mn |
| Mar 31, 2025 | 28.16 Mn |
| Dec 31, 2024 | 38.52 Mn |
| Sep 30, 2024 | 37.42 Mn |
| Jun 30, 2024 | 34.79 Mn |
| Mar 31, 2024 | 45.37 Mn |
| Dec 31, 2023 | 39.09 Mn |
| Sep 30, 2023 | 41.33 Mn |
| Jun 30, 2023 | 44.69 Mn |
| Mar 31, 2023 | 48.65 Mn |
| Dec 31, 2022 | 114.05 Mn |
| Sep 30, 2022 | 103.94 Mn |
| Jun 30, 2022 | 91.52 Mn |
| Mar 31, 2022 | 77.91 Mn |
| Dec 31, 2021 | 81.28 Mn |
| Sep 30, 2021 | 91.88 Mn |
| Jun 30, 2021 | 105.60 Mn |